Biogen Idec Inc. - Clinical Immunology

(Reuters) - U.S. regulators have extended their review of Biogen Idec Inc's application to update the prescribing information for its multiple sclerosis drug Tysabri, the company said on Thursday.Biogen, which sells the drug with Irish drugmaker Elan Corp Plc, is seeking to ...

BOSTON (Reuters) - Over the past year, Biogen Idec Inc has given investors little to complain about. The biotechnology company, operating under new management, has restructured its operations, reported promising clinical trial data and seen its shares rise 72 percent.The question is: ...

Company's Extensive Late-Stage Portfolio Could Address Unmet Patient Needs and Redefine Success in the Treatment of Multiple Sclerosis --. Data being presented will include Biogen Idec's currently marketed products, TYSABRI (natalizumab) and AVONEX (interferon beta-1a), as well as four late-stage programs: prolonged-release ...

We have a winner in the U.S. race to market a pill for multiple sclerosis - Novartis! Biogen shares slid today on fears Gilenya will compete with its existing MS therapies Avonex and Tysabri. Forbes' The Medicine Show blog notes the surprise ...

Biogen Idec Inc. (BIIB) reported second-quarter earnings per share of $1.27, well above the Zacks Consensus Estimate of $1.08 and the year-earlier figure of 73 cents. Biogen estimates that as of the end of June 2010, about 52,700 patients were on commercial ...

Biogen Idec Inc. said Tuesday its profit more than doubled in the second quarter compared to a year ago, when it entered a partnership on a potential multiple sclerosis drug.. Biogen's share of that revenue increased 17 percent to $219 million. Biogen ...

First of 1,500 Patients Enroll To Receive Monthly Injection [Chicago Tribune]. "Despite significant advances in MS therapy, many patients continue to experience disease activity," said Dr. Ludwig Kappos, lead investigator for the Abbott- and Biogen-funded study and head of MS research at ...

is often overused and misplaced, but in Gilenia's (fingolimod) case this is truly appropriate as it is on the verge of becoming the first oral drug to treat MS patients, up to 40% of whom are estimated to delay or refuse initial ...

Global in-market net sales of TYSABRI in the first quarter of 2010 were $292 million, an increase of 28% over the first quarter of 2009, of which $135 million were in the U.S. and $157 million were in rest of world markets. ...

Data suggests improvement across broad range of functional and quality of life measures -. The presented data, based on post-hoc analyses and patient-reported outcomes studies, highlights the ability of TYSABRI (natalizumab), in some multiple sclerosis (MS) patients, to improve sustained visual function, ...

Previous

1
2
3
4

Topic: Biogen Idec Inc.

FDA extends review of Tysabri JC virus label

Analysis: Biogen investors place bets ahead of MS drug trial

Biogen Idec Showcases Global, Multiple Sclerosis Leadership with More Than 45 Data Presentations at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis

Novartis Drug First to Cross Oral MS Therapy Finish Line in U.S.

Biogen Tops Estimates, Raises Guidance on Strong Pipeline

Biogen Second Quarter Profit Doubles Without Acorda Payment

Abbott Enters Final Clinical Trial Of MS Drug

Novartis: Gilenia Clears Latest Regulatory Hurdle With Ease

Biogen Idec Reports First Quarter 2010 Results Tysabri Revenues Increase 32% Year over Year

Large Body of Data on Tysabri to Be Presented at Annual Meeting of the American Academy of Neurology

From Around the Web

Video Gallery

Follow this Topic with...